PROVECTUS BIOPHARMACEUTICALS I (PVCT) Stock Price & Overview

NYSEARCA:PVCT • US74373P1084

Current stock price

0.05
-0.02 (-28.57%)
Last:

The current stock price of PVCT is 0.05 null. Today PVCT is down by -28.57%. In the past month the price decreased by -50%. In the past year, price decreased by -90.91%.

PVCT Key Statistics

52-Week Range0.05 - 0.55
Current PVCT stock price positioned within its 52-week range.
1-Month Range0.05 - 0.12
Current PVCT stock price positioned within its 1-month range.
Market Cap
18.518M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.05
Dividend Yield
N/A

PVCT Stock Performance

Today
-28.57%
1 Week
-28.57%
1 Month
-50.00%
3 Months
-83.87%
Longer-term
6 Months -85.71%
1 Year -90.91%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

PVCT Stock Chart

PROVECTUS BIOPHARMACEUTICALS I / PVCT Daily stock chart

PVCT Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to PVCT. When comparing the yearly performance of all stocks, PVCT is a bad performer in the overall market: 98.85% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
PVCT Full Technical Analysis Report

PVCT Earnings

Next Earnings DateApr 12, 2022
Last Earnings DateN/A
PeriodQ3 / 2024
EPS Reported$0.00
Revenue Reported110K
EPS Surprise %
Revenue Surprise %
PVCT Earnings History

PVCT Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
PVCT Forecast & Estimates

PVCT Financial Highlights

Over the last trailing twelve months PVCT reported a non-GAAP Earnings per Share(EPS) of -0.05.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)N/A
Industry RankSector Rank
PM (TTM) 100.15%
ROA -257.04%
ROE -478.66%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A
PVCT financials

PVCT Ownership

Ownership
Inst Owners0.06%
Shares370.36M
Float355.55M
Ins Owners8.24%
Short Float %0.23%
Short Ratio0.24
PVCT Ownership

About PVCT

Company Profile

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. The company's product portfolio consists of PV-10 Melanoma, PH-10 Psoriasis, PH-10 Atopic Dermatitis, PV-10 Breast Cancer, PV-10 Liver Metastasis and PV-10 Mechanism of Action which are in clinical trials. Provectus Biopharmaceuticals Inc., formerly known as Provectus Pharmaceuticals, Inc., is based in Knoxville, Tennessee.

Company Info

PROVECTUS BIOPHARMACEUTICALS I

7327 OAK RIDGE HIGHWAY SUITE A

KNOXVILLE TN 37931

CEO: Alfred E. Smith IV

Phone: 866-594-5999

PROVECTUS BIOPHARMACEUTICALS I / PVCT FAQ

What does PVCT do?

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. The company's product portfolio consists of PV-10 Melanoma, PH-10 Psoriasis, PH-10 Atopic Dermatitis, PV-10 Breast Cancer, PV-10 Liver Metastasis and PV-10 Mechanism of Action which are in clinical trials. Provectus Biopharmaceuticals Inc., formerly known as Provectus Pharmaceuticals, Inc., is based in Knoxville, Tennessee.


What is the current price of PVCT stock?

The current stock price of PVCT is 0.05 null. The price decreased by -28.57% in the last trading session.


Does PROVECTUS BIOPHARMACEUTICALS I pay dividends?

PVCT does not pay a dividend.


How is the ChartMill rating for PROVECTUS BIOPHARMACEUTICALS I?

PVCT has a ChartMill Technical rating of 0 out of 10.You can find more details on the Technical Analysis and Fundamental Analysis tabs.


Should I buy PVCT stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PVCT.


What is the outstanding short interest for PROVECTUS BIOPHARMACEUTICALS I?

The outstanding short interest for PROVECTUS BIOPHARMACEUTICALS I (PVCT) is 0.23% of its float.